Clinical Study of Paclitaxel for Injection(Albumin Bound)Combined with Hyperbaric Oxygen in the Treatment of Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer
Objective To investigate the clinical efficacy of Paclitaxel for Injection(Albumin Bound)combined with hyperbaric oxygen in the treatment of chemotherapy-induced peripheral neuropathy(CIPN)in breast cancer.Methods A total of 120 patients with breast cancer admitted to the hospital from January 2021 to December 2022 were selected and divided into the observation group and the control group according to the time of admission,with 60 cases in each group.The patients in the two groups were treated with Paclitaxel for Injection(Albumin Bound),while the patients in the observation group were treated with hyperbaric oxygen.Both groups were treated for four cycles with 21 d as one cycle.Results The objective remission rate(ORR)in the observation group was 56.67％,which was significantly higher than 36.67％in the control group(P＜0.05).The pathological complete remission(pCR)rate in the observation group was 53.33％,which was significantly higher than 30.00％in the control group(P＜0.05).After treatment,the visual analogue scale(VAS)score in the two groups was significantly lower than those before treatment(P＜0.05),and that in the observation group was significantly lower than that in the control group(P＜0.05);the motor conduction velocity(MCV)of the bilateral common peroneal nerve and the sensory conduction velocity(SCV)of the sural nerve in the two groups were significantly lower than those before treatment(P＜0.05),and those in the observation group were significantly higher than those in the control group(P＜0.05);the serum level of breast cancer 1(BRCA1)in the two groups was significantly lower than that before treatment(P＜0.05),and that in the observation group was significantly lower than that in the control group(P＜0.05);the level of recombinant forkhead box protein A1(FOXA1)in the two groups was significantly higher than that before treatment(P＜0.05),and that in the observation group was significantly higher than that in the control group(P＜0.05).The incidence of adverse reactions was comparable between the observation group and the control group(8.33％vs.10.00％,P＞0.05).Conclusion Paclitaxel for Injection(Albumin Bound)combined with hyperbaric oxygen has good clinical efficacy and safety in the treatment of chemotherapy-induced CIPN in breast cancer,which can improve the average conduction velocity of electromyography and the level of tumor suppressor genes caused by chemotherapy,and alleviate the pain degree of CIPN.
Paclitaxel for Injection(Albumin Bound)hyperbaric oxygenbreast cancerchemotherapyperipheral neuropathy
万方数据
维普
